CA3217096A1 - Contraceptive compounds and methods - Google Patents

Contraceptive compounds and methods Download PDF

Info

Publication number
CA3217096A1
CA3217096A1 CA3217096A CA3217096A CA3217096A1 CA 3217096 A1 CA3217096 A1 CA 3217096A1 CA 3217096 A CA3217096 A CA 3217096A CA 3217096 A CA3217096 A CA 3217096A CA 3217096 A1 CA3217096 A1 CA 3217096A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
independently selected
c6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3217096A
Other languages
English (en)
French (fr)
Inventor
Ingrid Gunda Georg
Narsihmulu CHERYALA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3217096A1 publication Critical patent/CA3217096A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3217096A 2021-05-04 2022-05-03 Contraceptive compounds and methods Pending CA3217096A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163184014P 2021-05-04 2021-05-04
US63/184,014 2021-05-04
US202263307943P 2022-02-08 2022-02-08
US63/307,943 2022-02-08
US202263326524P 2022-04-01 2022-04-01
US63/326,524 2022-04-01
PCT/US2022/027506 WO2022235693A1 (en) 2021-05-04 2022-05-03 Contraceptive compounds and methods

Publications (1)

Publication Number Publication Date
CA3217096A1 true CA3217096A1 (en) 2022-11-10

Family

ID=81854578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3217096A Pending CA3217096A1 (en) 2021-05-04 2022-05-03 Contraceptive compounds and methods

Country Status (9)

Country Link
US (3) US11780828B2 (https=)
EP (1) EP4334309A1 (https=)
JP (1) JP7828661B2 (https=)
KR (1) KR20240004737A (https=)
AU (1) AU2022270088A1 (https=)
CA (1) CA3217096A1 (https=)
IL (1) IL308171A (https=)
MX (1) MX2023012958A (https=)
WO (1) WO2022235693A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7828661B2 (ja) * 2021-05-04 2026-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 避妊薬の化合物及び方法
WO2025251031A1 (en) * 2024-05-30 2025-12-04 Yourchoice Therapeutics, Inc. Contraceptive compounds and dosing for the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CN1255396C (zh) * 1996-03-18 2006-05-10 卫材株式会社 含有稠环的羧酸衍生物
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
AU2015365738B2 (en) * 2014-12-19 2020-07-23 Galderma Research & Development Novel compounds, synthesis method thereof and use of same in medicine and in cosmetics
WO2017201200A1 (en) * 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
WO2019014468A1 (en) * 2017-07-13 2019-01-17 Io Therapeutics, Inc. RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY
EP3709990A4 (en) * 2017-11-17 2021-12-01 The Regents of the University of California MANIPULATION OF THE RETIC ACID SIGNAL PATH
JP7828661B2 (ja) * 2021-05-04 2026-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 避妊薬の化合物及び方法

Also Published As

Publication number Publication date
US20250276962A1 (en) 2025-09-04
US20220388993A1 (en) 2022-12-08
US12281105B2 (en) 2025-04-22
AU2022270088A1 (en) 2023-11-23
EP4334309A1 (en) 2024-03-13
KR20240004737A (ko) 2024-01-11
JP7828661B2 (ja) 2026-03-12
IL308171A (en) 2023-12-01
MX2023012958A (es) 2024-01-05
JP2024516023A (ja) 2024-04-11
US11780828B2 (en) 2023-10-10
US20240109872A1 (en) 2024-04-04
WO2022235693A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JP7656589B2 (ja) エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
US20250276962A1 (en) Contraceptive compounds and methods
JP5815237B2 (ja) 核内受容体結合剤
CN114945566A (zh) 作为钠通道调节剂的取代四氢呋喃
CA3054809A1 (en) Uses of pyrimidopyrimidinones as sik inhibitors
TWI701249B (zh) Ｋv１.３抑制劑及其醫學應用
KR20170076673A (ko) Kcnq2∼5 채널 활성화제
WO2021041975A1 (en) Perk inhibiting pyrrolopyrimidine compounds
WO2017189613A1 (en) Methods of using fasn inhibitors
KR102628396B1 (ko) 샤프롱-매개 자가포식 조절제로서 유용한 화합물
CN110156674A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
WO2022201097A1 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
JP6903266B2 (ja) １，２ナフトキノン誘導体及びその製造方法
US7071205B2 (en) 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
WO2019129114A1 (zh) 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用
US12209078B2 (en) Crystalline forms of carbazole inhibitors of RhoGTPase for the treatment of disease
CN117881674A (zh) 避孕化合物和方法
JP2025508983A (ja) 重水素化レチノイド化合物ならびにその合成および使用
JP7657223B2 (ja) 炎症性疾患および男性避妊用ｒａｒアルファ化合物
JP2020502283A (ja) インドールアミン−２，３−ジオキシゲナーゼ阻害剤としてのスルホニルアミディーン及びその製造方法と用途
WO2016200817A1 (en) Beta-naphthoisoflavones, compositions containing, and uses of, same
RU2712624C9 (ru) Композиции для лечения заболевания почек и/или печени
JP2025144382A (ja) 化合物、アジュバント組成物および医薬組成物
KR100520334B1 (ko) 안염치료에사용하기위한니트론화합물함유조성물
HK40119524A (zh) 三环类化合物及其用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250425